INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 428m ago
HOUSE PTR27m ago
SEC 13F27m ago
ROBINHOOD CHAIN27m ago
SEC FORM 4/Grant or awardVerified data

Lezack Adam reported BBNX

Director · Beta Bionics, Inc. · Common Stock

Side
A
Value
—
Shares
3,997
Price
—
Executed
Jan 13, 2026
Disclosed
Jan 14, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jan 13 executedJan 14, 2026 disclosed

BBNX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 47.4% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    4 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BBNX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    3
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$6,253
    370 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    6
    MM
    Mensinger MikeChief Product Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$58K
    2,650 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    3
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$16K
    821 sh
    		Oct 26, 2026Oct 28, 2026
    traded Oct 26, 2026
    		+2dSEC FORM 4

    Evidence

    19
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$13K
    775 sh
    		Oct 14, 2026Oct 16, 2026
    traded Oct 14, 2026
    		+2dSEC FORM 4

    Evidence

    19
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$7,015
    370 sh
    		Oct 1, 2026Oct 5, 2026
    traded Oct 1, 2026
    		+4dSEC FORM 4

    Evidence

    22
    JC
    Jones ChristyDirector
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$148K
    6,430 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    16
    MM
    Mensinger MikeChief Product Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$58K
    2,650 sh
    		Sep 16, 2026Sep 17, 2026
    traded Sep 16, 2026
    		+1dSEC FORM 4

    Evidence

    27
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$620K
    30.8K sh
    		Sep 16, 2026Sep 17, 2026
    traded Sep 16, 2026
    		+1dSEC FORM 4

    Evidence

    13
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$12K
    775 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    27
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$681K
    36.9K sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    19
    SS
    Saint SeanDirector, President & CEO
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$113K
    5,641 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    35
    FS
    Feider StephenChief Financial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$128K
    6,675 sh
    		Sep 2, 2026Sep 3, 2026
    traded Sep 2, 2026
    		+1dSEC FORM 4

    Evidence

    38
    SS
    Saint SeanDirector, President & CEO
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$322K
    16.9K sh
    		Sep 2, 2026Sep 3, 2026
    traded Sep 2, 2026
    		+1dSEC FORM 4

    Evidence

    35
    MM
    Mensinger MikeChief Product Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$84K
    4,375 sh
    		Sep 2, 2026Sep 3, 2026
    traded Sep 2, 2026
    		+1dSEC FORM 4

    Evidence

    35
    RJ
    Russell Steven JonChief Medical Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$81K
    4,221 sh
    		Sep 2, 2026Sep 3, 2026
    traded Sep 2, 2026
    		+1dSEC FORM 4

    Evidence

    32
    HM
    Hopman MarkChief Commercial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale
    		SELL$102K
    5,327 sh
    		Sep 2, 2026Sep 3, 2026
    traded Sep 2, 2026
    		+1dSEC FORM 4

    Evidence

    0
    FS
    Feider StephenChief Financial Officer
    BBNXBeta Bionics, Inc.
    Option exercise · 10b5-1 plan
    		M$25K
    4,982 sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    0
    FS
    Feider StephenChief Financial Officer
    BBNXBeta Bionics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    4,982 sh
    		Jun 26, 2026Jun 30, 2026
    traded Jun 26, 2026
    		+4dSEC FORM 4

    Evidence

    14
    FS
    Feider StephenChief Financial Officer
    BBNXBeta Bionics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$83K
    4,896 sh
    		Jun 29, 2026Jun 30, 2026
    traded Jun 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    FS
    Feider StephenChief Financial Officer
    BBNXBeta Bionics, Inc.
    Option exercise · 10b5-1 plan
    		M$25K
    4,896 sh
    		Jun 29, 2026Jun 30, 2026
    traded Jun 29, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002048466-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 13, 2026
    Published
    Jan 14, 2026
    Ingested by INSIDER
    Nov 5, 04:22 UTC
    Last re-read
    Nov 5, 04:22 UTC

    Extracted facts

    Filer
    Lezack Adam
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Beta Bionics, Inc.
    Ticker
    BBNX
    Shares
    3,997
    Price per share
    $0
    Execution date (reported)
    Jan 13, 2026
    Owned after transaction
    12.4K shares
    Days from execution to publication
    1

    What this establishes

    Lezack Adam filed this Form 4 reporting a grant or award of BBNX on Jan 13, 2026. It became public on Jan 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Lezack Adamcik:0002048466
    Issuer
    Beta Bionics, Inc.cik:0001674632

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.